Table 1.
Calculating the cost (2000 US dollars) of using suppressive valacyclovir therapy to achieve a 30% reduction in the population incidence of HSV-2 genital herpes.
| Population in USA 2000 (72) | $281,421,906.00 |
| Population with HSV-2 (17%) (4) | $47,841,724.00 |
| 30% of population with HSV-2 | $14,352,517.00 |
| Yearly drug costs per individual | $1,168.30 |
| Drug costs at 30% coverage | $16,768,045,850.00 |
| Yearly lifetime incident cost (51) | $1,800,000,000.00 |
| Yearly savings from preventions | $540,000,000.00 |
| Cost of genital herpes per year (32) | $1,353,405,133.00 |
| Savings due to fewer individuals seeking medical care, assuming 67% of covered individuals will have no recurrence (57) | $272,034,432.00 |
| 3 years of savings | $816,103,295.00 |
| 3 years of drug therapy | $50,304,137,550.00 |
| Net cost | $49,488,034,255.00 |